{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "code",
      "execution_count": 9,
      "metadata": {
        "id": "v8RS-qEMx4PZ",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "71466a40-64ec-4cc2-c877-1581a2e61624"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "[nltk_data] Downloading package wordnet to /root/nltk_data...\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "True"
            ]
          },
          "metadata": {},
          "execution_count": 9
        }
      ],
      "source": [
        "import pandas as pd\n",
        "import os\n",
        "import re\n",
        "import nltk\n",
        "from spacy import displacy\n",
        "nltk.download('wordnet')"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "path = '/content/drive/MyDrive/Colab-Notebooks/test/data/test_task_data.txt'\n"
      ],
      "metadata": {
        "id": "gd7w6pYiyGw8"
      },
      "execution_count": 3,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "with open(path, \"r\") as f:\n",
        "    text = f.read()"
      ],
      "metadata": {
        "id": "xG2cIdWm21K3"
      },
      "execution_count": 4,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "text"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 123
        },
        "id": "JPmsVfcz3Xu_",
        "outputId": "9ac5bef2-cab9-4e18-a23c-e655717ff07d"
      },
      "execution_count": 5,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'Earth beyond six of nine planetary boundaries.\\n15 September, 2023\\n\\nFiNuTyper: Design and validation of an automated deep learning-based platform for simultaneous fiber and nucleus type analysis in human skeletal muscle.\\nSeptember, 2023\\n\\nCOURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success.\\nAugust, 2023\\n\\nEconomic evaluation of Motor Neuron Diseases: a nationwide cross-sectional analysis in Germany\\nJune, 2023\\n\\nPeripheral Nerve Ultrasound for the Differentiation between ALS, Inflammatory, and Hereditary Polyneuropathies\\nJune, 2023\\n\\nGuideline \"Motor neuron diseases\" of the German Society of Neurology (Deutsche Gesellschaft für Neurologie)\\nJune, 2023\\n\\nPerformance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis-a cross-sectional multicenter study.\\nJune, 2023\\n\\nMultimodal layer modeling reveals in-vivo pathology in ALS\\nJune, 2023\\n\\nEpilepsy in a mouse model of GNB1 encephalopathy arises from altered potassium (GIRK) channel signaling and is alleviated by a GIRK inhibitor.\\n18 May, 2023\\n\\nSpectrum and frequency of genetic variants in sporadic amyotrophic lateral sclerosis.\\n9 May, 2023\\n\\nCOURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success\\nMay, 2023\\n\\nImprovement of muscle strength in specific muscular regions in nusinersen-treated adult patients with 5q-spinal muscular atrophy\\nApril, 2023\\n\\nAn observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy\\nApril, 2023\\n\\nClinical and genetic features of amyotrophic lateral sclerosis patients with C9orf72 mutations.\\n21 March, 2023\\n\\nAssociation of the practice of contact sports with the development of amyotrophic lateral sclerosis\\nMarch, 2023\\n\\nNeurofilament light chain response during therapy with antisense oligonucleotide Tofersen in SOD1 ‐related ALS – treatment experience in clinical practice\\nMarch, 2023\\n\\nCDNF rescues motor neurons in models of amyotrophic lateral sclerosis by targeting endoplasmic reticulum stress\\nMarch, 2023\\n\\nPerformance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis – a cross‐sectional multicenter study\\nMarch, 2023\\n\\nCranial nerve involvement in patients with immune-mediated neuropathy: An observational blink reflex study\\nMarch, 2023\\n\\nTrends in the diagnostic delay and pathway for amyotrophic lateral sclerosis patients across different countries\\nJanuary, 2023\\n\\nALSFRS-R-SE English public December 2022.pdf\\nJanuary, 2023\\n\\nALSFRS-R-SE Deutsch public Dezember 2022.pdf\\nJanuary, 2023\\n\\nHealth-Related Quality of Life in Spinal Muscular Atrophy Patients and Their Caregivers—A Prospective, Cross-Sectional, Multi-Center Analysis\\nJanuary, 2023\\n\\nImprovements in Walking Distance during Nusinersen Treatment - A Prospective 3-year SMArtCARE Registry Study.\\n2023\\n\\nALSFRS-R-SE: an adapted, annotated, and self-explanatory version of the revised amyotrophic lateral sclerosis functional rating scale.\\n15 December, 2022\\n\\nOral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment\\nDecember, 2022\\n\\nModes of Pangean lake level cyclicity driven by astronomical climate pacing modulated by continental position and pCO[Formula: see text].\\n16 November, 2022\\n\\nTowards the Validation of Executive Functioning Assessments: A Clinical Study\\nNovember, 2022\\n\\nAltered Immunomodulatory Responses in the CX3CL1/CX3CR1 Axis Mediated by hMSCs in an Early In Vitro SOD1G93A Model of ALS\\nNovember, 2022\\n\\nImproved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.\\n23 October, 2022\\n\\nTauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: The TUDCA-ALS trial protocol.\\n27 September, 2022\\n\\nFeasibility of audio-motor training with the multisensory device ABBI: Implementation in a child with hemiplegia and hemianopia.\\n9 September, 2022\\n\\nGlial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy.\\nSeptember, 2022\\n\\nPrevalence of Anti-Adeno-Associated Virus Serotype 9 Antibodies in Adult Patients with Spinal Muscular Atrophy.\\nSeptember, 2022\\n\\nA SUMO4 initiator codon variant in amyotrophic lateral sclerosis reduces SUMO4 expression and alters stress granule dynamics.\\nSeptember, 2022\\n\\nAmyotrophic lateral sclerosis\\nSeptember, 2022\\n\\nRemote digital assessment of amyotrophic lateral sclerosis functional rating scale – a multicenter observational study\\nAugust, 2022\\n\\nPrevalence of Anti-AAV9 Antibodies in Adult Patients with Spinal Muscular Atrophy\\nAugust, 2022\\n\\nProgress in spinal muscular atrophy research\\nAugust, 2022\\n\\nMotor Influence in Developing Auditory Spatial Cognition in Hemiplegic Children with and without Visual Field Disorder.\\n15 July, 2022\\n\\nAmyotrophe Lateralsklerose und andere Motoneuronerkrankungen: Pathophysiologie, Diagnostik und Therapie\\nJuly, 2022\\n\\nHypercoagulability in COVID-19: from an unknown beginning to future therapies.\\nJuly, 2022\\n\\nAnalysis of routine blood parameters in patients with amyotrophic lateral sclerosis and evaluation of a possible correlation with disease progression—a multicenter study\\nJuly, 2022\\n\\nLong-term outcomes of transaxillary versus video-assisted first rib resection for neurogenic thoracic outlet syndrome.\\n15 June, 2022\\n\\nCharacteristics of pain and the burden it causes in patients with amyotrophic lateral sclerosis - a longitudinal study.\\nMay, 2022\\n\\n[Advance Care Planning-further development of the patient advance directive : What the specialist in internal medicine must know].\\nMay, 2022\\n\\nAlteration of Mitochondrial Integrity as Upstream Event in the Pathophysiology of SOD1-ALS\\nApril, 2022\\n\\nAuthor Correction: Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology.\\nMarch, 2022\\n\\nModerne Diagnosestellung der Amyotrophen Lateralsklerose – ein Update der Diagnosekriterien\\nMarch, 2022\\n\\nAn Automated Tongue Tracker for Quantifying Bulbar Function in ALS.\\n25 February, 2022\\n\\nAn Automated Tongue Tracker for Quantifying Bulbar Function in ALS\\nFebruary, 2022\\n\\nValidity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy\\nFebruary, 2022\\n\\nClinical trials in pediatric ALS: a TRICALS feasibility study\\nFebruary, 2022\\n\\nPain-Related Coping Behavior in ALS: The Interplay between Maladaptive Coping, the Patient’s Affective State and Pain\\nFebruary, 2022\\n\\nSafety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis\\nJanuary, 2022\\n\\nMajor research advances in amyotrophic lateral sclerosis in 2021.\\nJanuary, 2022\\n\\nOsmanovic&Gogol et al_Supplementary Material.pdf\\nJanuary, 2022\\n\\nHeterozygous DHTKD1 Variants in Two European Cohorts of Amyotrophic Lateral Sclerosis Patients.\\n29 December, 2021\\n\\nExecutive function is inversely correlated with physical function: the cognitive profile of adult Spinal Muscular Atrophy (SMA)\\nDecember, 2021\\n\\nCommon and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology.\\nDecember, 2021\\n\\nGlial Fibrillary Acidic Protein in Cerebrospinal Fluid of Nusinersen-Treated Patients with Spinal Muscular Atrophy\\nNovember, 2021\\n\\nMethylation and Expression of Mutant FUS in Motor Neurons Differentiated From Induced Pluripotent Stem Cells From ALS Patients\\nNovember, 2021\\n\\nA selectable all-in-one CRISPR prime editing piggyBac transposon allows for highly efficient gene editing in human cell lines\\nNovember, 2021\\n\\nDelayed Diagnosis and Diagnostic Pathway of ALS Patients in Portugal: Where Can We Improve?\\nOctober, 2021\\n\\nSafety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.\\nOctober, 2021\\n\\nSafety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial\\nOctober, 2021\\n\\nA Multi-Center Cohort Study on Characteristics of Pain, Its Impact and Pharmacotherapeutic Management in Patients with ALS.\\n30 September, 2021\\n\\nBrain activity is contingent on neuropsychological function in a functional magnetic resonance imaging study of verbal working memory in amyotrophic lateral sclerosis.\\nSeptember, 2021\\n\\nCharacteristics of pain and the burden it causes in patients with amyotrophic lateral sclerosis – a longitudinal study\\nAugust, 2021\\n\\nIncreased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy.\\n28 July, 2021\\n\\nMotor neuron disease beginning with frontotemporal dementia: clinical features and progression\\nJuly, 2021\\n\\nCaregivers\\' Burden of School-Aged Children with Neurodevelopmental Disorders: Implications for Family-Centred Care.\\n30 June, 2021\\n\\nInvestigating Mesozoic Climate Trends and Sensitivities With a Large Ensemble of Climate Model Simulations.\\nJune, 2021\\n\\nBrain activity is contingent on neuropsychological function in an fMRI study of Verbal Working Memory in Amyotrophic Lateral Sclerosis\\nJune, 2021\\n\\nInformal Caregiving in Amyotrophic Lateral Sclerosis (ALS): A High Caregiver Burden and Drastic Consequences on Caregivers’ Lives\\nJune, 2021\\n\\nCaregivers’ divergent perspectives on patients’ well-being and attitudes towards hastened death in Germany, Poland and Sweden\\nJune, 2021\\n\\nImpairment of mitochondrial oxidative phosphorylation in skin fibroblasts of SALS and FALS patients is rescued by in vitro treatment with ROS scavengers.\\nMay, 2021\\n\\nChitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study.\\nMay, 2021\\n\\nTreatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen\\nMay, 2021\\n\\nSupplTables.docx\\nMay, 2021\\n\\nFigureS3.pdf\\nMay, 2021\\n\\nReconditioning the Neurogenic Niche of Adult Non-human Primates by Antisense Oligonucleotide-Mediated Attenuation of TGFβ Signaling\\nApril, 2021\\n\\nAn observational cohort study on impact, dimensions and outcome of perceived fatigue in adult 5q-spinal muscular atrophy patients receiving nusinersen treatment\\nMarch, 2021\\n\\nTreatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy\\nMarch, 2021\\n\\nNusinersen Wearing-Off in Adult 5q-Spinal Muscular Atrophy Patients\\nMarch, 2021\\n\\nA Nation-Wide, Multi-Center Study on the Quality of Life of ALS Patients in Germany\\nMarch, 2021\\n\\nSerum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment\\nMarch, 2021\\n\\nCerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients.\\n26 February, 2021\\n\\nAn early endothelial cell-specific requirement for Glut1 is revealed in Glut1 deficiency syndrome model mice.\\n8 February, 2021\\n\\nChitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study View supplementary material Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study\\nFebruary, 2021\\n\\nClinically Applicable Quantitative Magnetic Resonance Morphologic Measurements of Grey Matter Changes in the Human Brain.\\n5 January, 2021\\n\\nAnschriften der Herausgeber und Autoren\\nJanuary, 2021\\n\\nFUS Is Not Mislocalized in Spinal Motor Neurons Derived From Human Induced Pluripotent Stem Cells of Main Non-FUS ALS Subtypes\\nJanuary, 2021\\n\\nImpairment of mitochondrial oxidative phosphorylation in skin fibroblasts of SALS and FALS patients is rescued by in vitro treatment with ROS scavengers\\nJanuary, 2021\\n\\nLongitudinal clinical and neuroanatomical correlates of memory impairment in motor neuron disease.\\n2021\\n\\nThe genetic landscape of axonal neuropathies in the middle-aged and elderly: Focus on MME.\\n15 December, 2020\\n\\nCognitive Performance of Patients with Adult 5q-Spinal Muscular Atrophy and with Amyotrophic Lateral Sclerosis\\nDecember, 2020\\n\\nPeripheral neuropathy in ALS: phenotype association\\nDecember, 2020\\n\\nCardiovascular comorbidities in amyotrophic lateral sclerosis\\nDecember, 2020\\n\\nCosts of illness in amyotrophic lateral sclerosis (ALS): A cross-sectional survey in Germany\\nDecember, 2020\\n\\nTextural markers of ultrasonographic nerve alterations in amyotrophic lateral sclerosis.\\nNovember, 2020\\n\\nReduced GABAergic Neuron Excitability, Altered Synaptic Connectivity, and Seizures in a KCNT1 Gain-of-Function Mouse Model of Childhood Epilepsy.\\n27 October, 2020\\n\\nEmotional Lability at Disease Onset Is an Independent Prognostic Factor of Faster Disease Progression in Amyotrophic Lateral Sclerosis\\nOctober, 2020\\n\\nALS and fertility: does ALS affect number of children patients have?\\nSeptember, 2020\\n\\nSPG7 mutations in amyotrophic lateral sclerosis: a genetic link to hereditary spastic paraplegia\\nSeptember, 2020\\n\\nEffect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis.\\nSeptember, 2020\\n\\nA Computational Study of Executive Dysfunction in Amyotrophic Lateral Sclerosis\\nAugust, 2020\\n\\nTreatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy\\nAugust, 2020\\n\\nDyspnea as a Fatigue-Promoting Factor in ALS and the Role of Objective Indicators of Respiratory Impairment.\\nAugust, 2020\\n\\nAnalysis of shared common genetic risk between amyotrophic lateral sclerosis and epilepsy.\\nAugust, 2020\\n\\nRNAi-Based Gene Therapy Rescues Developmental and Epileptic Encephalopathy in a Genetic Mouse Model.\\n8 July, 2020\\n\\nErratum zu: SARS-CoV-2/COVID-19 und neuromuskuläre ErkrankungenErratum to: SARS-CoV-2/COVID-19 and neuromuscular disorders: Bestandsaufnahme der DGN (Deutsche Gesellschaft für Neurologie) Kommission Motoneuron- und neuromuskuläre ErkrankungenAn overview of the DGN (German Neurological Society) Commission on Motor Neuron and Neuromuscular Diseases\\nJuly, 2020\\n\\nImpact of comorbidities and co-medication on disease onset and progression in a large German ALS patient group\\nJuly, 2020\\n\\nModelling and treating GRIN2A developmental and epileptic encephalopathy in mice.\\n1 July, 2020\\n\\nSpreading in ALS: The relative impact of upper and lower motor neuron involvement\\nJune, 2020\\n\\nAre cancer patients better off if they participate in clinical trials? A mixed methods study.\\n8 May, 2020\\n\\nOsmanovic et al_JNeurol2020_Supplementary material.pdf\\nMay, 2020\\n\\nPotential Preventive Strategies for Amyotrophic Lateral Sclerosis\\nMay, 2020\\n\\nCDNF rescues motor neurons in three animal models of ALS by targeting ER stress\\nMay, 2020\\n\\n[Implementing patient-centered advance care planning in the outpatient setting during the COVID-19 pandemic].\\nMay, 2020\\n\\nAltered excitatory transmission onto hippocampal interneurons in the IQSEC2 mouse model of X-linked neurodevelopmental disease.\\nApril, 2020\\n\\nNusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.\\nApril, 2020\\n\\nSymptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme\\nApril, 2020\\n\\nAmyotrophic Lateral Sclerosis and COVID-19 – Recommendations to patients and caregivers\\nApril, 2020\\n\\n7T MR neurography-ultrasound fusion for peripheral nerve imaging.\\nApril, 2020\\n\\nFamily history of neurodegenerative disorders in patients with amyotrophic lateral sclerosis: population-based case–control study\\nMarch, 2020\\n\\nDyspnea as a Fatigue-Promoting Factor in ALS and the Role of Objective Indicators of Respiratory Impairment\\nMarch, 2020\\n\\nSonographic and 3T-MRI-based evaluation of the tongue in ALS\\nMarch, 2020\\n\\nThe upper cervical spinal cord in ALS assessed by cross-sectional and longitudinal 3T MRI.\\n4 February, 2020\\n\\nKnocking out C9ORF72 Exacerbates Axonal Trafficking Defects Associated with Hexanucleotide Repeat Expansion and Reduces Levels of Heat Shock Proteins\\nFebruary, 2020\\n\\nThe upper cervical spinal cord in ALS assessed by cross-sectional and longitudinal 3T MRI\\nFebruary, 2020\\n\\n[Advance Care Planning-further development of the patient advance directive : What the anesthetist must know].\\nFebruary, 2020\\n\\nArfgef1 haploinsufficiency in mice alters neuronal endosome composition and decreases membrane surface postsynaptic GABAA receptors.\\nFebruary, 2020\\n\\nNeurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.\\nJanuary, 2020\\n\\nSonographic and 3T-MRI-based evaluation of the tongue in ALS.\\n2020\\n\\nReply: Adult-onset distal spinal muscular atrophy: a new phenotype associated with KIF5A mutations.\\n1 December, 2019\\n\\nEffect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis\\nDecember, 2019\\n\\nThe Dyspnea-ALS-Scale (DALS-15) optimizes individual treatment in patients with amyotrophic lateral sclerosis (ALS) suffering from dyspnea\\nDecember, 2019\\n\\nTranscriptome-wide Profiling of Cerebral Cavernous Malformations Patients Reveal Important Long noncoding RNA molecular signatures\\nDecember, 2019\\n\\nIncobotulinumtoxinA for hypersalivation in patients with amyotrophic lateral sclerosis: an open-label single-centre study.\\nOctober, 2019\\n\\nDECREASE OF BRAIN REGIONAL CORTICAL THICKNESS IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS\\nOctober, 2019\\n\\nAltered calcium dynamics and glutamate receptor properties in iPSC-derived motor neurons from ALS patients with C9orf72, FUS, SOD1 or TDP43 mutations.\\n1 September, 2019\\n\\nIsoform-selective as opposed to complete depletion of fibroblast growth factor 2 (FGF-2) has no major impact on survival and gene expression in SOD1G93A amyotrophic lateral sclerosis mice.\\nSeptember, 2019\\n\\nRoutine Cerebrospinal Fluid Cytology Reveals Unique Inclusions in Macrophages During Treatment With Nusinersen.\\n11 July, 2019\\n\\nDyspnea in amyotrophic lateral sclerosis: The Dyspnea-ALS-Scale (DALS-15) essentially contributes to the diagnosis of respiratory impairment.\\nJuly, 2019\\n\\nThe Dyspnea-ALS-Scale (DALS-15) optimizes individual treatment in patients with amyotrophic lateral sclerosis (ALS) suffering from dyspnea.\\n3 June, 2019\\n\\nNusinersen bei spinaler Muskelatrophie: Klinische Anwendbarkeit bei erwachsenen Patienten mit SMA Typ II\\nJune, 2019\\n\\nExpression of the axon-guidance protein receptor Neuropilin 1 is increased in the spinal cord and decreased in muscle of a mouse model of amyotrophic lateral sclerosis.\\nJune, 2019\\n\\nPrognostic factors in ALS: a comparison between Germany and China.\\nJune, 2019\\n\\nNeurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment.\\n10 May, 2019\\n\\nCharacterizing the multiple roles of FGF-2 in SOD1G93A ALS mice in vivo and in vitro.\\nMay, 2019\\n\\nTherapie mit Edaravone bei der Amyotrophen Lateralsklerose\\nMay, 2019\\n\\nEine hochkalorische, fettreiche Nahrungsergänzung für ALS-Patienten: Ergebnisse einer multizentrischen, randomisierten, placebo-kontrollierten Studie im Deutschen Netzwerk für Motoneuronerkrankungen (LIPCAL-ALS-Studie)\\nMay, 2019\\n\\nUntersuchung von NfL und pNfH im Liquor von Jugendlichen und Erwachsenen mit spinaler Muskelatrophie (SMA) Typ 2 und 3 unter der Therapie mit Nusinersen\\nMay, 2019\\n\\nToward in vivo determination of peripheral nervous system immune activity in amyotrophic lateral sclerosis.\\nMay, 2019\\n\\nAnalysis of the therapeutic potential of different administration routes and frequencies of human mesenchymal stromal cells in the SOD1G93A mouse model of amyotrophic lateral sclerosis.\\nApril, 2019\\n\\nInfluence of Environment and Lifestyle on Incidence and Progress of Amyotrophic Lateral Sclerosis in A German ALS Population.\\n1 April, 2019\\n\\nROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis.\\n27 March, 2019\\n\\nHybrid Sterility with Meiotic Metaphase Arrest in Intersubspecific Mouse Crosses.\\n5 March, 2019\\n\\nROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis\\nMarch, 2019\\n\\nTowards in vivo determination of peripheral nervous system immune activity in ALS\\nFebruary, 2019\\n\\nA phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis.\\n2019\\n\\nWhen Nursing Care and Clinical Trials Coincide: A Qualitative Study of the Views of Nordic Oncology and Hematology Nurses on Ethical Work Challenges.\\nDecember, 2018\\n\\nDysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS.\\nDecember, 2018\\n\\nIncobotulinumtoxinA for hypersalivation in patients with amyotrophic lateral sclerosis\\nDecember, 2018\\n\\nSignificance of CSF NfL and tau in ALS.\\nNovember, 2018\\n\\nDyspnea in Amyotrophic Lateral Sclerosis: Rasch-Based Development and Validation of a Patient-Reported Outcome (DALS-15).\\nNovember, 2018\\n\\nProjected changes in persistent extreme summer weather events: The role of quasi-resonant amplification.\\n31 October, 2018\\n\\nCharacterizing the multiple roles of FGF-2 in SOD1 G93A ALS mice in vivo and in vitro: KEFALAKES et al.\\nOctober, 2018\\n\\nQuantitative Susceptibility MRI to Detect Brain Iron in Amyotrophic Lateral Sclerosis.\\nOctober, 2018\\n\\nAlberta wildfire 2016: Apt contribution from anomalous planetary wave dynamics.\\n17 August, 2018\\n\\nAssociation between attention-deficit/hyperactivity disorder (ADHD) and amyotrophic lateral sclerosis (ALS).\\n15 August, 2018\\n\\nProvision of assistive technology devices among people with ALS in Germany: a platform-case management approach.\\nAugust, 2018\\n\\nComprehensive analysis of the mutation spectrum in 301 German ALS families.\\nAugust, 2018\\n\\nSafety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.\\nAugust, 2018\\n\\nImplementing Motor Unit Number Index (MUNIX) in a large clinical trial: Real world experience from 27 centres.\\nAugust, 2018\\n\\nP38. Longitudinal sonographic alterations of the peripheral nerve structure in ALS\\nAugust, 2018\\n\\nP37. Various sonographic gray-scale measures of the peripheral nerve differ between ALS and ALS disease mimics\\nAugust, 2018\\n\\nGlobal Hippocampal Volume Reductions and Local CA1 Shape Deformations in Amyotrophic Lateral Sclerosis.\\n20 July, 2018\\n\\nTherapeutic decisions in ALS patients: cross-cultural differences and clinical implications.\\nJuly, 2018\\n\\nAge-dependent neurodegeneration and organelle transport deficiencies in mutant TDP43 patient-derived neurons are independent of TDP43 aggregation.\\nJuly, 2018\\n\\nDifferential involvement of forearm muscles in ALS does not relate to sonographic structural nerve alterations.\\nJuly, 2018\\n\\nThe metabolic and endocrine characteristics in spinal and bulbar muscular atrophy.\\nMay, 2018\\n\\nPrognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model.\\nMay, 2018\\n\\nSupplementary Data\\nMarch, 2018\\n\\nPercutaneous endoscopic gastrostomy with and without jejunal extension in patients with amyotrophic lateral sclerosis.\\nMarch, 2018\\n\\nHot-spot KIF5A mutations cause familial ALS.\\n1 March, 2018\\n\\nPeripheral nerve atrophy together with higher cerebrospinal fluid progranulin indicate axonal damage in amyotrophic lateral sclerosis.\\nFebruary, 2018\\n\\nImpaired DNA damage response signaling by FUS-NLS mutations leads to neurodegeneration and FUS aggregate formation.\\n23 January, 2018\\n\\nMulticenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis.\\n2 January, 2018\\n\\nSupplementary Material 1\\nJanuary, 2018\\n\\nThe TGF-β System As a Potential Pathogenic Player in Disease Modulation of Amyotrophic Lateral Sclerosis.\\n15 December, 2017'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 5
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "text = re.sub(r\"\\n\", \" \", text)\n",
        "text_2 = text"
      ],
      "metadata": {
        "id": "WqTQWXb53eMP"
      },
      "execution_count": 6,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def pre_procesing(text):\n",
        "    date_pattern1 = r'\\b\\d{1,2} (January|February|March|April|May|June|July|August|September|October|November|December), \\d{4}\\b'\n",
        "    date_pattern2 = r'\\b(January|February|March|April|May|June|July|August|September|October|November|December), \\d{4}\\b'\n",
        "    year_pattern = r'\\b\\d{4}\\b'\n",
        "    month_pattern = r'\\b(January|February|March|April|May|June|July|August|September|October|November|December)\\b'\n",
        "    punctuation_pattern = r'[^\\w\\s]'\n",
        "\n",
        "    cleaned_text = re.sub(date_pattern1, '', text)\n",
        "    cleaned_text = re.sub(date_pattern2, '', cleaned_text)\n",
        "    cleaned_text = re.sub(year_pattern, '', cleaned_text)\n",
        "    cleaned_text = re.sub(month_pattern, '', cleaned_text)\n",
        "    cleaned_text = re.sub(punctuation_pattern, '', cleaned_text)\n",
        "\n",
        "    words = cleaned_text.split()\n",
        "    lemmatizer = nltk.WordNetLemmatizer()\n",
        "    words = [lemmatizer.lemmatize(word) for word in words]\n",
        "\n",
        "    return \" \".join(words)"
      ],
      "metadata": {
        "id": "7L_VyhG53_GJ"
      },
      "execution_count": 7,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "text = pre_procesing(text)\n",
        "text"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 123
        },
        "id": "FeoQQY8z4EA-",
        "outputId": "212d0779-f34b-4403-b77a-481bbbf18be0"
      },
      "execution_count": 10,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'Earth beyond six of nine planetary boundary FiNuTyper Design and validation of an automated deep learningbased platform for simultaneous fiber and nucleus type analysis in human skeletal muscle COURAGEALS a randomized doubleblind phase 3 study designed to improve participant experience and increase the probability of success Economic evaluation of Motor Neuron Diseases a nationwide crosssectional analysis in Germany Peripheral Nerve Ultrasound for the Differentiation between ALS Inflammatory and Hereditary Polyneuropathies Guideline Motor neuron disease of the German Society of Neurology Deutsche Gesellschaft für Neurologie Performance of serum neurofilament light chain in a wide spectrum of clinical course of amyotrophic lateral sclerosisa crosssectional multicenter study Multimodal layer modeling reveals invivo pathology in ALS Epilepsy in a mouse model of GNB1 encephalopathy arises from altered potassium GIRK channel signaling and is alleviated by a GIRK inhibitor Spectrum and frequency of genetic variant in sporadic amyotrophic lateral sclerosis COURAGEALS a randomized doubleblind phase 3 study designed to improve participant experience and increase the probability of success Improvement of muscle strength in specific muscular region in nusinersentreated adult patient with 5qspinal muscular atrophy An observational cohort study on pulmonary function in adult patient with 5qspinal muscular atrophy under nusinersen therapy Clinical and genetic feature of amyotrophic lateral sclerosis patient with C9orf72 mutation Association of the practice of contact sport with the development of amyotrophic lateral sclerosis Neurofilament light chain response during therapy with antisense oligonucleotide Tofersen in SOD1 related ALS treatment experience in clinical practice CDNF rescue motor neuron in model of amyotrophic lateral sclerosis by targeting endoplasmic reticulum stress Performance of serum neurofilament light chain in a wide spectrum of clinical course of amyotrophic lateral sclerosis a crosssectional multicenter study Cranial nerve involvement in patient with immunemediated neuropathy An observational blink reflex study Trends in the diagnostic delay and pathway for amyotrophic lateral sclerosis patient across different country ALSFRSRSE English public pdf ALSFRSRSE Deutsch public Dezember pdf HealthRelated Quality of Life in Spinal Muscular Atrophy Patients and Their CaregiversA Prospective CrossSectional MultiCenter Analysis Improvements in Walking Distance during Nusinersen Treatment A Prospective 3year SMArtCARE Registry Study ALSFRSRSE an adapted annotated and selfexplanatory version of the revised amyotrophic lateral sclerosis functional rating scale Oral edaravone demonstrated a favorable safety profile in patient with amyotrophic lateral sclerosis after 48 week of treatment Modes of Pangean lake level cyclicity driven by astronomical climate pacing modulated by continental position and pCOFormula see text Towards the Validation of Executive Functioning Assessments A Clinical Study Altered Immunomodulatory Responses in the CX3CL1CX3CR1 Axis Mediated by hMSCs in an Early In Vitro SOD1G93A Model of ALS Improved upper limb function in nonambulant child with SMA type 2 and 3 during nusinersen treatment a prospective 3years SMArtCARE registry study Tauroursodeoxycholic acid in patient with amyotrophic lateral sclerosis The TUDCAALS trial protocol Feasibility of audiomotor training with the multisensory device ABBI Implementation in a child with hemiplegia and hemianopia Glial fibrillary acidic protein in cerebrospinal fluid of patient with spinal muscular atrophy Prevalence of AntiAdenoAssociated Virus Serotype 9 Antibodies in Adult Patients with Spinal Muscular Atrophy A SUMO4 initiator codon variant in amyotrophic lateral sclerosis reduces SUMO4 expression and alters stress granule dynamic Amyotrophic lateral sclerosis Remote digital assessment of amyotrophic lateral sclerosis functional rating scale a multicenter observational study Prevalence of AntiAAV9 Antibodies in Adult Patients with Spinal Muscular Atrophy Progress in spinal muscular atrophy research Motor Influence in Developing Auditory Spatial Cognition in Hemiplegic Children with and without Visual Field Disorder Amyotrophe Lateralsklerose und andere Motoneuronerkrankungen Pathophysiologie Diagnostik und Therapie Hypercoagulability in COVID19 from an unknown beginning to future therapy Analysis of routine blood parameter in patient with amyotrophic lateral sclerosis and evaluation of a possible correlation with disease progressiona multicenter study Longterm outcome of transaxillary versus videoassisted first rib resection for neurogenic thoracic outlet syndrome Characteristics of pain and the burden it cause in patient with amyotrophic lateral sclerosis a longitudinal study Advance Care Planningfurther development of the patient advance directive What the specialist in internal medicine must know Alteration of Mitochondrial Integrity a Upstream Event in the Pathophysiology of SOD1ALS Author Correction Common and rare variant association analysis in amyotrophic lateral sclerosis identify 15 risk locus with distinct genetic architecture and neuronspecific biology Moderne Diagnosestellung der Amyotrophen Lateralsklerose ein Update der Diagnosekriterien An Automated Tongue Tracker for Quantifying Bulbar Function in ALS An Automated Tongue Tracker for Quantifying Bulbar Function in ALS Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy Clinical trial in pediatric ALS a TRICALS feasibility study PainRelated Coping Behavior in ALS The Interplay between Maladaptive Coping the Patients Affective State and Pain Safety and Effectiveness of Longterm Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis Major research advance in amyotrophic lateral sclerosis in OsmanovicGogol et al_Supplementary Materialpdf Heterozygous DHTKD1 Variants in Two European Cohorts of Amyotrophic Lateral Sclerosis Patients Executive function is inversely correlated with physical function the cognitive profile of adult Spinal Muscular Atrophy SMA Common and rare variant association analysis in amyotrophic lateral sclerosis identify 15 risk locus with distinct genetic architecture and neuronspecific biology Glial Fibrillary Acidic Protein in Cerebrospinal Fluid of NusinersenTreated Patients with Spinal Muscular Atrophy Methylation and Expression of Mutant FUS in Motor Neurons Differentiated From Induced Pluripotent Stem Cells From ALS Patients A selectable allinone CRISPR prime editing piggyBac transposon allows for highly efficient gene editing in human cell line Delayed Diagnosis and Diagnostic Pathway of ALS Patients in Portugal Where Can We Improve Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis the REFALS study a randomised doubleblind placebocontrolled phase 3 trial Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis the REFALS study a randomised doubleblind placebocontrolled phase 3 trial A MultiCenter Cohort Study on Characteristics of Pain Its Impact and Pharmacotherapeutic Management in Patients with ALS Brain activity is contingent on neuropsychological function in a functional magnetic resonance imaging study of verbal working memory in amyotrophic lateral sclerosis Characteristics of pain and the burden it cause in patient with amyotrophic lateral sclerosis a longitudinal study Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy Motor neuron disease beginning with frontotemporal dementia clinical feature and progression Caregivers Burden of SchoolAged Children with Neurodevelopmental Disorders Implications for FamilyCentred Care Investigating Mesozoic Climate Trends and Sensitivities With a Large Ensemble of Climate Model Simulations Brain activity is contingent on neuropsychological function in an fMRI study of Verbal Working Memory in Amyotrophic Lateral Sclerosis Informal Caregiving in Amyotrophic Lateral Sclerosis ALS A High Caregiver Burden and Drastic Consequences on Caregivers Lives Caregivers divergent perspective on patient wellbeing and attitude towards hastened death in Germany Poland and Sweden Impairment of mitochondrial oxidative phosphorylation in skin fibroblast of SALS and FALS patient is rescued by in vitro treatment with ROS scavenger Chitotriosidase a biomarker for early stage amyotrophic lateral sclerosis a multicenter study Treatment expectation and perception of therapy in adult patient with spinal muscular atrophy receiving nusinersen SupplTablesdocx FigureS3pdf Reconditioning the Neurogenic Niche of Adult Nonhuman Primates by Antisense OligonucleotideMediated Attenuation of TGFβ Signaling An observational cohort study on impact dimension and outcome of perceived fatigue in adult 5qspinal muscular atrophy patient receiving nusinersen treatment Treatment satisfaction in 5qspinal muscular atrophy under nusinersen therapy Nusinersen WearingOff in Adult 5qSpinal Muscular Atrophy Patients A NationWide MultiCenter Study on the Quality of Life of ALS Patients in Germany Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment Cerebrospinal Fluid Parameters in Antisense OligonucleotideTreated Adult 5qSpinal Muscular Atrophy Patients An early endothelial cellspecific requirement for Glut1 is revealed in Glut1 deficiency syndrome model mouse Chitotriosidase a biomarker for early stage amyotrophic lateral sclerosis a multicenter study View supplementary material Chitotriosidase a biomarker for early stage amyotrophic lateral sclerosis a multicenter study Clinically Applicable Quantitative Magnetic Resonance Morphologic Measurements of Grey Matter Changes in the Human Brain Anschriften der Herausgeber und Autoren FUS Is Not Mislocalized in Spinal Motor Neurons Derived From Human Induced Pluripotent Stem Cells of Main NonFUS ALS Subtypes Impairment of mitochondrial oxidative phosphorylation in skin fibroblast of SALS and FALS patient is rescued by in vitro treatment with ROS scavenger Longitudinal clinical and neuroanatomical correlate of memory impairment in motor neuron disease The genetic landscape of axonal neuropathy in the middleaged and elderly Focus on MME Cognitive Performance of Patients with Adult 5qSpinal Muscular Atrophy and with Amyotrophic Lateral Sclerosis Peripheral neuropathy in ALS phenotype association Cardiovascular comorbidities in amyotrophic lateral sclerosis Costs of illness in amyotrophic lateral sclerosis ALS A crosssectional survey in Germany Textural marker of ultrasonographic nerve alteration in amyotrophic lateral sclerosis Reduced GABAergic Neuron Excitability Altered Synaptic Connectivity and Seizures in a KCNT1 GainofFunction Mouse Model of Childhood Epilepsy Emotional Lability at Disease Onset Is an Independent Prognostic Factor of Faster Disease Progression in Amyotrophic Lateral Sclerosis ALS and fertility doe ALS affect number of child patient have SPG7 mutation in amyotrophic lateral sclerosis a genetic link to hereditary spastic paraplegia Effect of highcaloric nutrition on serum neurofilament light chain level in amyotrophic lateral sclerosis A Computational Study of Executive Dysfunction in Amyotrophic Lateral Sclerosis Treatment expectation and patientreported outcome of nusinersen therapy in adult spinal muscular atrophy Dyspnea a a FatiguePromoting Factor in ALS and the Role of Objective Indicators of Respiratory Impairment Analysis of shared common genetic risk between amyotrophic lateral sclerosis and epilepsy RNAiBased Gene Therapy Rescues Developmental and Epileptic Encephalopathy in a Genetic Mouse Model Erratum zu SARSCoV2COVID19 und neuromuskuläre ErkrankungenErratum to SARSCoV2COVID19 and neuromuscular disorder Bestandsaufnahme der DGN Deutsche Gesellschaft für Neurologie Kommission Motoneuron und neuromuskuläre ErkrankungenAn overview of the DGN German Neurological Society Commission on Motor Neuron and Neuromuscular Diseases Impact of comorbidities and comedication on disease onset and progression in a large German ALS patient group Modelling and treating GRIN2A developmental and epileptic encephalopathy in mouse Spreading in ALS The relative impact of upper and lower motor neuron involvement Are cancer patient better off if they participate in clinical trial A mixed method study Osmanovic et al_JNeurol2020_Supplementary materialpdf Potential Preventive Strategies for Amyotrophic Lateral Sclerosis CDNF rescue motor neuron in three animal model of ALS by targeting ER stress Implementing patientcentered advance care planning in the outpatient setting during the COVID19 pandemic Altered excitatory transmission onto hippocampal interneurons in the IQSEC2 mouse model of Xlinked neurodevelopmental disease Nusinersen in adult with 5q spinal muscular atrophy a noninterventional multicentre observational cohort study Symptomatic pharmacotherapy in ALS data analysis from a platformbased medication management programme Amyotrophic Lateral Sclerosis and COVID19 Recommendations to patient and caregiver 7T MR neurographyultrasound fusion for peripheral nerve imaging Family history of neurodegenerative disorder in patient with amyotrophic lateral sclerosis populationbased casecontrol study Dyspnea a a FatiguePromoting Factor in ALS and the Role of Objective Indicators of Respiratory Impairment Sonographic and 3TMRIbased evaluation of the tongue in ALS The upper cervical spinal cord in ALS assessed by crosssectional and longitudinal 3T MRI Knocking out C9ORF72 Exacerbates Axonal Trafficking Defects Associated with Hexanucleotide Repeat Expansion and Reduces Levels of Heat Shock Proteins The upper cervical spinal cord in ALS assessed by crosssectional and longitudinal 3T MRI Advance Care Planningfurther development of the patient advance directive What the anesthetist must know Arfgef1 haploinsufficiency in mouse alters neuronal endosome composition and decrease membrane surface postsynaptic GABAA receptor Neurofilament light chain in serum of adolescent and adult SMA patient under treatment with nusinersen Sonographic and 3TMRIbased evaluation of the tongue in ALS Reply Adultonset distal spinal muscular atrophy a new phenotype associated with KIF5A mutation Effect of HighCaloric Nutrition on Survival in Amyotrophic Lateral Sclerosis The DyspneaALSScale DALS15 optimizes individual treatment in patient with amyotrophic lateral sclerosis ALS suffering from dyspnea Transcriptomewide Profiling of Cerebral Cavernous Malformations Patients Reveal Important Long noncoding RNA molecular signature IncobotulinumtoxinA for hypersalivation in patient with amyotrophic lateral sclerosis an openlabel singlecentre study DECREASE OF BRAIN REGIONAL CORTICAL THICKNESS IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS Altered calcium dynamic and glutamate receptor property in iPSCderived motor neuron from ALS patient with C9orf72 FUS SOD1 or TDP43 mutation Isoformselective a opposed to complete depletion of fibroblast growth factor 2 FGF2 ha no major impact on survival and gene expression in SOD1G93A amyotrophic lateral sclerosis mouse Routine Cerebrospinal Fluid Cytology Reveals Unique Inclusions in Macrophages During Treatment With Nusinersen Dyspnea in amyotrophic lateral sclerosis The DyspneaALSScale DALS15 essentially contributes to the diagnosis of respiratory impairment The DyspneaALSScale DALS15 optimizes individual treatment in patient with amyotrophic lateral sclerosis ALS suffering from dyspnea Nusinersen bei spinaler Muskelatrophie Klinische Anwendbarkeit bei erwachsenen Patienten mit SMA Typ II Expression of the axonguidance protein receptor Neuropilin 1 is increased in the spinal cord and decreased in muscle of a mouse model of amyotrophic lateral sclerosis Prognostic factor in ALS a comparison between Germany and China Neurochemical marker in CSF of adolescent and adult SMA patient undergoing nusinersen treatment Characterizing the multiple role of FGF2 in SOD1G93A ALS mouse in vivo and in vitro Therapie mit Edaravone bei der Amyotrophen Lateralsklerose Eine hochkalorische fettreiche Nahrungsergänzung für ALSPatienten Ergebnisse einer multizentrischen randomisierten placebokontrollierten Studie im Deutschen Netzwerk für Motoneuronerkrankungen LIPCALALSStudie Untersuchung von NfL und pNfH im Liquor von Jugendlichen und Erwachsenen mit spinaler Muskelatrophie SMA Typ 2 und 3 unter der Therapie mit Nusinersen Toward in vivo determination of peripheral nervous system immune activity in amyotrophic lateral sclerosis Analysis of the therapeutic potential of different administration route and frequency of human mesenchymal stromal cell in the SOD1G93A mouse model of amyotrophic lateral sclerosis Influence of Environment and Lifestyle on Incidence and Progress of Amyotrophic Lateral Sclerosis in A German ALS Population ROCKALS Protocol for a Randomized PlaceboControlled DoubleBlind Phase IIa Trial of Safety Tolerability and Efficacy of the Rho Kinase ROCK Inhibitor Fasudil in Amyotrophic Lateral Sclerosis Hybrid Sterility with Meiotic Metaphase Arrest in Intersubspecific Mouse Crosses ROCKALS Protocol for a Randomized PlaceboControlled DoubleBlind Phase IIa Trial of Safety Tolerability and Efficacy of the Rho Kinase ROCK Inhibitor Fasudil in Amyotrophic Lateral Sclerosis Towards in vivo determination of peripheral nervous system immune activity in ALS A phase III trial of tirasemtiv a a potential treatment for amyotrophic lateral sclerosis When Nursing Care and Clinical Trials Coincide A Qualitative Study of the Views of Nordic Oncology and Hematology Nurses on Ethical Work Challenges Dysregulation of a novel miRTBCBTUBA4A pathway in sporadic and familial ALS IncobotulinumtoxinA for hypersalivation in patient with amyotrophic lateral sclerosis Significance of CSF NfL and tau in ALS Dyspnea in Amyotrophic Lateral Sclerosis RaschBased Development and Validation of a PatientReported Outcome DALS15 Projected change in persistent extreme summer weather event The role of quasiresonant amplification Characterizing the multiple role of FGF2 in SOD1 G93A ALS mouse in vivo and in vitro KEFALAKES et al Quantitative Susceptibility MRI to Detect Brain Iron in Amyotrophic Lateral Sclerosis Alberta wildfire Apt contribution from anomalous planetary wave dynamic Association between attentiondeficithyperactivity disorder ADHD and amyotrophic lateral sclerosis ALS Provision of assistive technology device among people with ALS in Germany a platformcase management approach Comprehensive analysis of the mutation spectrum in 301 German ALS family Safety and efficacy of rasagiline a an addon therapy to riluzole in patient with amyotrophic lateral sclerosis a randomised doubleblind parallelgroup placebocontrolled phase 2 trial Implementing Motor Unit Number Index MUNIX in a large clinical trial Real world experience from 27 centre P38 Longitudinal sonographic alteration of the peripheral nerve structure in ALS P37 Various sonographic grayscale measure of the peripheral nerve differ between ALS and ALS disease mimic Global Hippocampal Volume Reductions and Local CA1 Shape Deformations in Amyotrophic Lateral Sclerosis Therapeutic decision in ALS patient crosscultural difference and clinical implication Agedependent neurodegeneration and organelle transport deficiency in mutant TDP43 patientderived neuron are independent of TDP43 aggregation Differential involvement of forearm muscle in ALS doe not relate to sonographic structural nerve alteration The metabolic and endocrine characteristic in spinal and bulbar muscular atrophy Prognosis for patient with amyotrophic lateral sclerosis development and validation of a personalised prediction model Supplementary Data Percutaneous endoscopic gastrostomy with and without jejunal extension in patient with amyotrophic lateral sclerosis Hotspot KIF5A mutation cause familial ALS Peripheral nerve atrophy together with higher cerebrospinal fluid progranulin indicate axonal damage in amyotrophic lateral sclerosis Impaired DNA damage response signaling by FUSNLS mutation lead to neurodegeneration and FUS aggregate formation Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis Supplementary Material The TGFβ System As a Potential Pathogenic Player in Disease Modulation of Amyotrophic Lateral Sclerosis'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 10
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import spacy"
      ],
      "metadata": {
        "id": "FiVBSxAO4Fq_"
      },
      "execution_count": 11,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "nlp = spacy.load(\"en_core_sci_sm\")"
      ],
      "metadata": {
        "id": "8P_N-qv7NQu3"
      },
      "execution_count": 19,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "doc = nlp(text)"
      ],
      "metadata": {
        "id": "1SMTjR2dZNLU"
      },
      "execution_count": 20,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "medicine_dict = []\n",
        "for ent in doc.ents:\n",
        "    medicine_dict.append(ent.text)"
      ],
      "metadata": {
        "id": "6Jnofk-OZmtl"
      },
      "execution_count": 21,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "medicine_dict"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "kwB2L0JHaDMb",
        "outputId": "3cc6ef8e-febe-4f4d-f383-f5cff50bc230"
      },
      "execution_count": 22,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['planetary',\n",
              " 'boundary',\n",
              " 'FiNuTyper Design',\n",
              " 'validation',\n",
              " 'automated',\n",
              " 'deep learningbased',\n",
              " 'simultaneous',\n",
              " 'fiber',\n",
              " 'nucleus type analysis',\n",
              " 'human',\n",
              " 'skeletal muscle',\n",
              " 'COURAGEALS',\n",
              " 'randomized doubleblind phase 3 study',\n",
              " 'participant',\n",
              " 'experience',\n",
              " 'increase',\n",
              " 'probability',\n",
              " 'success',\n",
              " 'Economic evaluation',\n",
              " 'Motor Neuron Diseases',\n",
              " 'Germany',\n",
              " 'Peripheral Nerve',\n",
              " 'Ultrasound',\n",
              " 'Differentiation',\n",
              " 'ALS',\n",
              " 'Inflammatory',\n",
              " 'Hereditary Polyneuropathies',\n",
              " 'Guideline',\n",
              " 'Motor neuron disease',\n",
              " 'German Society of Neurology Deutsche Gesellschaft',\n",
              " 'Neurologie',\n",
              " 'Performance',\n",
              " 'serum neurofilament light chain',\n",
              " 'clinical course',\n",
              " 'amyotrophic lateral sclerosisa',\n",
              " 'multicenter study',\n",
              " 'Multimodal layer modeling',\n",
              " 'pathology',\n",
              " 'ALS',\n",
              " 'Epilepsy',\n",
              " 'mouse model',\n",
              " 'GNB1 encephalopathy',\n",
              " 'potassium GIRK',\n",
              " 'GIRK inhibitor',\n",
              " 'Spectrum',\n",
              " 'frequency',\n",
              " 'genetic variant',\n",
              " 'sporadic',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'COURAGEALS',\n",
              " 'randomized doubleblind phase 3 study',\n",
              " 'participant',\n",
              " 'experience',\n",
              " 'increase',\n",
              " 'probability',\n",
              " 'success',\n",
              " 'Improvement',\n",
              " 'muscle strength',\n",
              " 'muscular region',\n",
              " 'adult',\n",
              " 'patient',\n",
              " '5qspinal',\n",
              " 'muscular atrophy',\n",
              " 'observational cohort study',\n",
              " 'pulmonary function',\n",
              " 'adult',\n",
              " 'patient',\n",
              " '5qspinal muscular atrophy',\n",
              " 'nusinersen therapy',\n",
              " 'Clinical',\n",
              " 'genetic feature',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'patient',\n",
              " 'C9orf72',\n",
              " 'mutation',\n",
              " 'Association',\n",
              " 'practice',\n",
              " 'contact sport',\n",
              " 'development',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'therapy',\n",
              " 'antisense oligonucleotide',\n",
              " 'Tofersen',\n",
              " 'SOD1',\n",
              " 'ALS',\n",
              " 'treatment',\n",
              " 'clinical practice',\n",
              " 'motor neuron',\n",
              " 'model',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'targeting',\n",
              " 'endoplasmic reticulum stress',\n",
              " 'Performance',\n",
              " 'serum neurofilament light chain',\n",
              " 'clinical course',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'crosssectional',\n",
              " 'multicenter study',\n",
              " 'Cranial nerve',\n",
              " 'involvement',\n",
              " 'patient',\n",
              " 'immunemediated neuropathy',\n",
              " 'observational blink reflex study',\n",
              " 'Trends',\n",
              " 'diagnostic delay',\n",
              " 'pathway',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'patient',\n",
              " 'country',\n",
              " 'ALSFRSRSE',\n",
              " 'English',\n",
              " 'public',\n",
              " 'Deutsch public Dezember',\n",
              " 'HealthRelated Quality of Life',\n",
              " 'Spinal Muscular Atrophy',\n",
              " 'Patients',\n",
              " 'CaregiversA Prospective CrossSectional',\n",
              " 'MultiCenter Analysis',\n",
              " 'Improvements',\n",
              " 'Walking Distance',\n",
              " 'Nusinersen Treatment',\n",
              " 'Study',\n",
              " 'ALSFRSRSE',\n",
              " 'annotated',\n",
              " 'selfexplanatory version',\n",
              " 'revised',\n",
              " 'amyotrophic lateral sclerosis functional rating scale',\n",
              " 'Oral edaravone',\n",
              " 'safety',\n",
              " 'patient',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'week',\n",
              " 'treatment',\n",
              " 'Modes',\n",
              " 'Pangean lake level cyclicity',\n",
              " 'astronomical climate',\n",
              " 'pacing',\n",
              " 'modulated',\n",
              " 'continental position',\n",
              " 'pCOFormula',\n",
              " 'Validation',\n",
              " 'Executive Functioning',\n",
              " 'Assessments',\n",
              " 'Clinical Study',\n",
              " 'Immunomodulatory Responses',\n",
              " 'CX3CL1CX3CR1 Axis',\n",
              " 'hMSCs',\n",
              " 'Early',\n",
              " 'In Vitro',\n",
              " 'SOD1G93A Model',\n",
              " 'ALS',\n",
              " 'upper limb function',\n",
              " 'nonambulant',\n",
              " 'child',\n",
              " 'SMA',\n",
              " 'nusinersen treatment',\n",
              " 'SMArtCARE registry study',\n",
              " 'Tauroursodeoxycholic acid',\n",
              " 'patient',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'TUDCAALS',\n",
              " 'trial',\n",
              " 'protocol',\n",
              " 'Feasibility',\n",
              " 'audiomotor training',\n",
              " 'multisensory device ABBI',\n",
              " 'Implementation',\n",
              " 'child',\n",
              " 'hemiplegia',\n",
              " 'Glial fibrillary acidic protein',\n",
              " 'cerebrospinal fluid',\n",
              " 'patient',\n",
              " 'spinal muscular atrophy',\n",
              " 'Prevalence',\n",
              " 'AntiAdenoAssociated Virus',\n",
              " 'Serotype 9 Antibodies',\n",
              " 'Adult',\n",
              " 'Patients',\n",
              " 'Spinal Muscular Atrophy',\n",
              " 'SUMO4 initiator',\n",
              " 'codon variant',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'SUMO4',\n",
              " 'expression',\n",
              " 'alters',\n",
              " 'Amyotrophic lateral sclerosis Remote digital assessment',\n",
              " 'amyotrophic lateral sclerosis functional rating scale',\n",
              " 'multicenter observational study',\n",
              " 'Prevalence',\n",
              " 'AntiAAV9 Antibodies',\n",
              " 'Adult',\n",
              " 'Patients',\n",
              " 'Spinal Muscular Atrophy',\n",
              " 'Progress',\n",
              " 'spinal muscular atrophy',\n",
              " 'Influence',\n",
              " 'Auditory',\n",
              " 'Hemiplegic',\n",
              " 'Children',\n",
              " 'Visual Field Disorder Amyotrophe Lateralsklerose',\n",
              " 'Motoneuronerkrankungen',\n",
              " 'Pathophysiologie',\n",
              " 'Diagnostik und',\n",
              " 'Hypercoagulability',\n",
              " 'COVID19',\n",
              " 'therapy',\n",
              " 'Analysis',\n",
              " 'routine',\n",
              " 'blood parameter',\n",
              " 'patient',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'evaluation',\n",
              " 'correlation',\n",
              " 'disease progressiona',\n",
              " 'multicenter study',\n",
              " 'Longterm outcome',\n",
              " 'transaxillary',\n",
              " 'videoassisted first',\n",
              " 'neurogenic thoracic outlet syndrome',\n",
              " 'Characteristics',\n",
              " 'pain',\n",
              " 'burden',\n",
              " 'patient',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'longitudinal study Advance Care',\n",
              " 'Planningfurther',\n",
              " 'development',\n",
              " 'patient advance',\n",
              " 'specialist',\n",
              " 'internal medicine',\n",
              " 'Alteration',\n",
              " 'Mitochondrial',\n",
              " 'Integrity',\n",
              " 'Upstream Event',\n",
              " 'Pathophysiology',\n",
              " 'SOD1ALS Author',\n",
              " 'rare',\n",
              " 'variant',\n",
              " 'association analysis',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'risk locus',\n",
              " 'genetic architecture',\n",
              " 'neuronspecific biology',\n",
              " 'Diagnosestellung der Amyotrophen Lateralsklerose ein Update der',\n",
              " 'Diagnosekriterien',\n",
              " 'Automated',\n",
              " 'Tracker',\n",
              " 'Quantifying',\n",
              " 'Bulbar Function',\n",
              " 'ALS',\n",
              " 'Automated',\n",
              " 'Tracker',\n",
              " 'Quantifying',\n",
              " 'Bulbar Function',\n",
              " 'ALS',\n",
              " 'Validity',\n",
              " 'reliability',\n",
              " 'German multidimensional fatigue',\n",
              " 'inventory',\n",
              " 'spinal muscular atrophy',\n",
              " 'Clinical trial',\n",
              " 'pediatric',\n",
              " 'ALS',\n",
              " 'TRICALS',\n",
              " 'feasibility study',\n",
              " 'Coping',\n",
              " 'Behavior',\n",
              " 'ALS',\n",
              " 'Maladaptive',\n",
              " 'Patients',\n",
              " 'Affective State',\n",
              " 'Pain Safety',\n",
              " 'Effectiveness',\n",
              " 'Longterm',\n",
              " 'Intravenous Administration',\n",
              " 'Edaravone',\n",
              " 'Treatment',\n",
              " 'Patients',\n",
              " 'Amyotrophic Lateral Sclerosis Major research advance',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'OsmanovicGogol',\n",
              " 'Materialpdf',\n",
              " 'Heterozygous',\n",
              " 'DHTKD1',\n",
              " 'Variants',\n",
              " 'European Cohorts',\n",
              " 'Amyotrophic Lateral Sclerosis',\n",
              " 'Patients',\n",
              " 'Executive function',\n",
              " 'correlated',\n",
              " 'physical function',\n",
              " 'cognitive profile',\n",
              " 'adult',\n",
              " 'Spinal Muscular Atrophy',\n",
              " 'SMA',\n",
              " 'Common',\n",
              " 'rare',\n",
              " 'variant',\n",
              " 'association analysis',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'risk locus',\n",
              " 'genetic architecture',\n",
              " 'neuronspecific biology',\n",
              " 'Cerebrospinal Fluid',\n",
              " 'NusinersenTreated',\n",
              " 'Patients',\n",
              " 'Spinal Muscular Atrophy',\n",
              " 'Methylation',\n",
              " 'Expression',\n",
              " 'Mutant',\n",
              " 'FUS',\n",
              " 'Motor Neurons',\n",
              " 'Induced',\n",
              " 'ALS',\n",
              " 'Patients',\n",
              " 'selectable',\n",
              " 'CRISPR',\n",
              " 'prime',\n",
              " 'transposon',\n",
              " 'efficient',\n",
              " 'gene editing',\n",
              " 'human cell line',\n",
              " 'Delayed Diagnosis',\n",
              " 'Diagnostic Pathway',\n",
              " 'ALS',\n",
              " 'Patients',\n",
              " 'Portugal',\n",
              " 'Safety',\n",
              " 'efficacy',\n",
              " 'oral levosimendan',\n",
              " 'people',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'REFALS',\n",
              " 'study',\n",
              " 'randomised',\n",
              " 'Safety',\n",
              " 'efficacy',\n",
              " 'oral levosimendan',\n",
              " 'people',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'REFALS',\n",
              " 'study',\n",
              " 'randomised',\n",
              " 'MultiCenter Cohort Study',\n",
              " 'Characteristics',\n",
              " 'Pain',\n",
              " 'Impact',\n",
              " 'Pharmacotherapeutic Management',\n",
              " 'Patients',\n",
              " 'ALS',\n",
              " 'Brain activity',\n",
              " 'neuropsychological function',\n",
              " 'functional',\n",
              " 'magnetic resonance imaging',\n",
              " 'verbal working memory',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'Characteristics',\n",
              " 'pain',\n",
              " 'burden',\n",
              " 'patient',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'longitudinal study',\n",
              " 'Increased',\n",
              " 'concentration',\n",
              " 'nusinersen treatment',\n",
              " 'spinal muscular atrophy',\n",
              " 'Motor neuron disease',\n",
              " 'frontotemporal dementia',\n",
              " 'clinical feature',\n",
              " 'progression',\n",
              " 'Caregivers',\n",
              " 'Burden',\n",
              " 'SchoolAged Children',\n",
              " 'Neurodevelopmental Disorders',\n",
              " 'FamilyCentred Care',\n",
              " 'Investigating',\n",
              " 'Mesozoic Climate',\n",
              " 'Sensitivities',\n",
              " 'Climate Model',\n",
              " 'Simulations',\n",
              " 'Brain activity',\n",
              " 'neuropsychological function',\n",
              " 'fMRI study',\n",
              " 'Verbal Working Memory',\n",
              " 'Amyotrophic Lateral Sclerosis Informal',\n",
              " 'Caregiving',\n",
              " 'Amyotrophic Lateral Sclerosis ALS',\n",
              " 'Caregiver',\n",
              " 'Burden',\n",
              " 'Drastic',\n",
              " 'Consequences',\n",
              " 'Caregivers',\n",
              " 'Lives',\n",
              " 'Caregivers',\n",
              " 'divergent',\n",
              " 'perspective',\n",
              " 'patient wellbeing',\n",
              " 'attitude',\n",
              " 'hastened death',\n",
              " 'Germany',\n",
              " 'Poland',\n",
              " 'Sweden Impairment',\n",
              " 'mitochondrial',\n",
              " 'oxidative',\n",
              " 'phosphorylation',\n",
              " 'skin fibroblast',\n",
              " 'SALS',\n",
              " 'FALS',\n",
              " 'patient',\n",
              " 'in vitro',\n",
              " 'treatment',\n",
              " 'ROS',\n",
              " 'Chitotriosidase',\n",
              " 'biomarker',\n",
              " 'early stage',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'multicenter study',\n",
              " 'Treatment expectation',\n",
              " 'perception',\n",
              " 'therapy',\n",
              " 'adult',\n",
              " 'patient',\n",
              " 'spinal muscular atrophy',\n",
              " 'nusinersen SupplTablesdocx',\n",
              " 'Neurogenic Niche',\n",
              " 'Adult',\n",
              " 'Nonhuman',\n",
              " 'Primates',\n",
              " 'Antisense OligonucleotideMediated Attenuation',\n",
              " 'TGFβ Signaling',\n",
              " 'observational cohort study',\n",
              " 'impact',\n",
              " 'dimension',\n",
              " 'outcome',\n",
              " 'perceived',\n",
              " 'fatigue',\n",
              " 'adult',\n",
              " '5qspinal',\n",
              " 'muscular atrophy',\n",
              " 'patient',\n",
              " 'nusinersen treatment',\n",
              " 'Treatment satisfaction',\n",
              " '5qspinal',\n",
              " 'muscular atrophy',\n",
              " 'nusinersen therapy',\n",
              " 'Nusinersen WearingOff',\n",
              " 'Adult',\n",
              " 'Muscular Atrophy',\n",
              " 'Patients',\n",
              " 'NationWide',\n",
              " 'MultiCenter Study',\n",
              " 'Quality of Life',\n",
              " 'ALS',\n",
              " 'Patients',\n",
              " 'Germany',\n",
              " 'Serum creatine kinase',\n",
              " 'creatinine',\n",
              " 'adult',\n",
              " 'spinal muscular atrophy',\n",
              " 'nusinersen treatment',\n",
              " 'Cerebrospinal Fluid',\n",
              " 'Parameters',\n",
              " 'Antisense',\n",
              " 'Muscular Atrophy',\n",
              " 'Patients',\n",
              " 'Glut1',\n",
              " 'Glut1 deficiency syndrome',\n",
              " 'model',\n",
              " 'mouse',\n",
              " 'Chitotriosidase',\n",
              " 'biomarker',\n",
              " 'early stage',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'multicenter study',\n",
              " 'supplementary material',\n",
              " 'Chitotriosidase',\n",
              " 'biomarker',\n",
              " 'early stage',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'multicenter study',\n",
              " 'Clinically',\n",
              " 'Quantitative Magnetic Resonance Morphologic Measurements',\n",
              " 'Grey Matter',\n",
              " 'Changes',\n",
              " 'Human Brain',\n",
              " 'Herausgeber und Autoren',\n",
              " 'FUS',\n",
              " 'Mislocalized',\n",
              " 'Spinal Motor Neurons',\n",
              " 'Human',\n",
              " 'Induced',\n",
              " 'NonFUS',\n",
              " 'ALS',\n",
              " 'Subtypes',\n",
              " 'Impairment',\n",
              " 'mitochondrial',\n",
              " 'oxidative',\n",
              " 'phosphorylation',\n",
              " 'skin fibroblast',\n",
              " 'SALS',\n",
              " 'FALS',\n",
              " 'patient',\n",
              " 'in vitro',\n",
              " 'treatment',\n",
              " 'ROS',\n",
              " 'Longitudinal clinical',\n",
              " 'neuroanatomical',\n",
              " 'correlate',\n",
              " 'memory impairment',\n",
              " 'motor neuron disease',\n",
              " 'genetic landscape',\n",
              " 'axonal neuropathy',\n",
              " 'middleaged',\n",
              " 'elderly Focus',\n",
              " 'MME',\n",
              " 'Cognitive',\n",
              " 'Performance',\n",
              " 'Patients',\n",
              " 'Adult',\n",
              " 'Muscular Atrophy',\n",
              " 'Amyotrophic Lateral Sclerosis',\n",
              " 'Peripheral neuropathy',\n",
              " 'ALS',\n",
              " 'phenotype',\n",
              " 'association',\n",
              " 'Cardiovascular',\n",
              " 'comorbidities',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'Costs',\n",
              " 'illness',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'ALS',\n",
              " 'crosssectional survey',\n",
              " 'Germany',\n",
              " 'Textural marker',\n",
              " 'ultrasonographic nerve',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'Reduced',\n",
              " 'GABAergic Neuron',\n",
              " 'Excitability',\n",
              " 'Synaptic Connectivity',\n",
              " 'Seizures',\n",
              " 'KCNT1',\n",
              " 'GainofFunction',\n",
              " 'Childhood Epilepsy Emotional',\n",
              " 'Lability',\n",
              " 'Disease',\n",
              " 'Prognostic Factor',\n",
              " 'Progression',\n",
              " 'Amyotrophic Lateral Sclerosis',\n",
              " 'ALS',\n",
              " 'fertility',\n",
              " 'ALS',\n",
              " 'child',\n",
              " 'patient',\n",
              " 'SPG7',\n",
              " 'mutation',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'genetic',\n",
              " 'hereditary spastic paraplegia',\n",
              " 'Effect',\n",
              " 'highcaloric nutrition',\n",
              " 'serum neurofilament light chain',\n",
              " 'level',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'Computational Study',\n",
              " 'Executive Dysfunction',\n",
              " 'Amyotrophic Lateral Sclerosis',\n",
              " 'Treatment expectation',\n",
              " 'patientreported outcome',\n",
              " 'nusinersen therapy',\n",
              " 'adult',\n",
              " 'spinal muscular atrophy',\n",
              " 'Dyspnea',\n",
              " 'FatiguePromoting Factor',\n",
              " 'ALS',\n",
              " 'Objective',\n",
              " 'Indicators',\n",
              " 'Respiratory Impairment',\n",
              " 'genetic risk',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'epilepsy',\n",
              " 'Gene Therapy',\n",
              " 'Rescues',\n",
              " 'Developmental',\n",
              " 'Epileptic Encephalopathy',\n",
              " 'Genetic Mouse Model',\n",
              " 'SARSCoV2COVID19',\n",
              " 'neuromuskuläre',\n",
              " 'ErkrankungenErratum',\n",
              " 'SARSCoV2COVID19',\n",
              " 'neuromuscular disorder',\n",
              " 'Bestandsaufnahme',\n",
              " 'Neurologie Kommission',\n",
              " 'DGN',\n",
              " 'German Neurological Society Commission',\n",
              " 'Motor Neuron',\n",
              " 'Neuromuscular Diseases',\n",
              " 'Impact',\n",
              " 'comorbidities',\n",
              " 'comedication',\n",
              " 'disease onset',\n",
              " 'progression',\n",
              " 'German',\n",
              " 'ALS',\n",
              " 'patient group',\n",
              " 'Modelling',\n",
              " 'treating',\n",
              " 'GRIN2A',\n",
              " 'developmental',\n",
              " 'epileptic encephalopathy',\n",
              " 'mouse Spreading',\n",
              " 'ALS',\n",
              " 'impact',\n",
              " 'upper',\n",
              " 'motor neuron',\n",
              " 'involvement',\n",
              " 'cancer',\n",
              " 'patient',\n",
              " 'participate',\n",
              " 'clinical trial',\n",
              " 'mixed method study',\n",
              " 'materialpdf',\n",
              " 'Potential',\n",
              " 'Preventive Strategies',\n",
              " 'Amyotrophic Lateral Sclerosis CDNF rescue motor neuron',\n",
              " 'animal model',\n",
              " 'ALS',\n",
              " 'ER stress',\n",
              " 'Implementing',\n",
              " 'advance care',\n",
              " 'outpatient setting',\n",
              " 'COVID19',\n",
              " 'pandemic',\n",
              " 'excitatory transmission',\n",
              " 'hippocampal',\n",
              " 'interneurons',\n",
              " 'IQSEC2',\n",
              " 'mouse model',\n",
              " 'Xlinked neurodevelopmental disease',\n",
              " 'Nusinersen',\n",
              " 'adult',\n",
              " '5q',\n",
              " 'spinal muscular atrophy',\n",
              " 'noninterventional',\n",
              " 'Symptomatic',\n",
              " 'pharmacotherapy',\n",
              " 'ALS',\n",
              " 'data analysis',\n",
              " 'platformbased medication management programme',\n",
              " 'Amyotrophic Lateral Sclerosis',\n",
              " 'COVID19',\n",
              " 'Recommendations',\n",
              " 'patient',\n",
              " 'caregiver 7T MR neurographyultrasound fusion',\n",
              " 'peripheral nerve imaging',\n",
              " 'Family history',\n",
              " 'neurodegenerative disorder',\n",
              " 'patient',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'casecontrol study',\n",
              " 'Dyspnea',\n",
              " 'FatiguePromoting Factor',\n",
              " 'ALS',\n",
              " 'Objective',\n",
              " 'Indicators',\n",
              " 'Respiratory Impairment',\n",
              " 'Sonographic',\n",
              " 'evaluation',\n",
              " 'tongue',\n",
              " 'ALS',\n",
              " 'upper cervical spinal cord',\n",
              " 'ALS',\n",
              " 'assessed',\n",
              " 'crosssectional',\n",
              " 'Exacerbates',\n",
              " 'Axonal',\n",
              " 'Defects',\n",
              " 'Associated with',\n",
              " 'Hexanucleotide Repeat Expansion',\n",
              " 'Reduces',\n",
              " 'Levels',\n",
              " 'Heat Shock Proteins',\n",
              " 'upper cervical spinal cord',\n",
              " 'ALS',\n",
              " 'assessed',\n",
              " 'crosssectional',\n",
              " 'Planningfurther',\n",
              " 'development',\n",
              " 'patient advance',\n",
              " 'anesthetist',\n",
              " 'Arfgef1',\n",
              " 'haploinsufficiency',\n",
              " 'mouse alters',\n",
              " 'neuronal',\n",
              " 'composition',\n",
              " 'decrease',\n",
              " 'membrane surface',\n",
              " 'postsynaptic GABAA receptor',\n",
              " 'Neurofilament light chain',\n",
              " 'serum',\n",
              " 'adolescent',\n",
              " 'adult',\n",
              " 'SMA',\n",
              " 'patient',\n",
              " 'treatment',\n",
              " 'nusinersen Sonographic',\n",
              " 'evaluation',\n",
              " 'tongue',\n",
              " 'ALS',\n",
              " 'Reply',\n",
              " 'Adultonset distal',\n",
              " 'spinal muscular atrophy',\n",
              " 'phenotype',\n",
              " 'associated with',\n",
              " 'KIF5A mutation',\n",
              " 'Effect',\n",
              " 'HighCaloric Nutrition',\n",
              " 'Survival',\n",
              " 'Amyotrophic Lateral Sclerosis',\n",
              " 'DyspneaALSScale',\n",
              " 'DALS15',\n",
              " 'individual',\n",
              " 'treatment',\n",
              " 'patient',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'ALS',\n",
              " 'suffering',\n",
              " 'dyspnea',\n",
              " 'Transcriptomewide Profiling',\n",
              " 'Cerebral Cavernous Malformations',\n",
              " 'Patients',\n",
              " 'Long noncoding RNA',\n",
              " 'hypersalivation',\n",
              " 'patient',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'openlabel singlecentre',\n",
              " 'DECREASE',\n",
              " 'BRAIN REGIONAL',\n",
              " 'CORTICAL THICKNESS IN AMYOTROPHIC LATERAL SCLEROSIS',\n",
              " 'PATIENTS',\n",
              " 'Altered',\n",
              " 'calcium dynamic',\n",
              " 'glutamate receptor',\n",
              " 'property',\n",
              " 'iPSCderived',\n",
              " 'motor neuron',\n",
              " 'ALS',\n",
              " 'patient',\n",
              " 'C9orf72',\n",
              " 'SOD1',\n",
              " 'TDP43',\n",
              " 'mutation',\n",
              " 'Isoformselective',\n",
              " 'depletion',\n",
              " 'fibroblast growth factor 2',\n",
              " 'FGF2',\n",
              " 'impact',\n",
              " 'survival',\n",
              " 'gene expression',\n",
              " 'SOD1G93A amyotrophic lateral sclerosis mouse',\n",
              " 'Routine',\n",
              " 'Cerebrospinal Fluid Cytology',\n",
              " 'Unique',\n",
              " 'Inclusions',\n",
              " 'Macrophages',\n",
              " 'Treatment',\n",
              " 'Nusinersen Dyspnea',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'DyspneaALSScale DALS15',\n",
              " 'diagnosis',\n",
              " 'respiratory impairment',\n",
              " 'DyspneaALSScale DALS15',\n",
              " 'individual',\n",
              " 'treatment',\n",
              " 'patient',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'ALS',\n",
              " 'suffering',\n",
              " 'dyspnea',\n",
              " 'Nusinersen bei spinaler Muskelatrophie Klinische',\n",
              " 'Anwendbarkeit bei erwachsenen Patienten',\n",
              " 'SMA',\n",
              " 'Typ II',\n",
              " 'Expression',\n",
              " 'axonguidance protein receptor',\n",
              " 'increased',\n",
              " 'spinal cord',\n",
              " 'decreased',\n",
              " 'muscle',\n",
              " 'mouse model',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'Prognostic factor',\n",
              " 'ALS',\n",
              " 'Germany',\n",
              " 'China',\n",
              " 'Neurochemical marker',\n",
              " 'CSF',\n",
              " 'adolescent',\n",
              " 'adult',\n",
              " 'SMA',\n",
              " 'patient',\n",
              " 'nusinersen treatment',\n",
              " 'FGF2',\n",
              " 'SOD1G93A',\n",
              " 'ALS',\n",
              " 'mouse',\n",
              " 'in vivo',\n",
              " 'in vitro',\n",
              " 'mit Edaravone bei der Amyotrophen',\n",
              " 'Eine hochkalorische fettreiche',\n",
              " 'Nahrungsergänzung für ALSPatienten',\n",
              " 'randomisierten placebokontrollierten',\n",
              " 'Netzwerk',\n",
              " 'Motoneuronerkrankungen LIPCALALSStudie',\n",
              " 'Untersuchung von NfL',\n",
              " 'Liquor von Jugendlichen',\n",
              " 'Erwachsenen mit spinaler Muskelatrophie',\n",
              " 'SMA',\n",
              " 'in vivo',\n",
              " 'determination',\n",
              " 'peripheral nervous system',\n",
              " 'immune activity',\n",
              " 'amyotrophic lateral sclerosis Analysis',\n",
              " 'therapeutic',\n",
              " 'potential',\n",
              " 'administration',\n",
              " 'frequency',\n",
              " 'human',\n",
              " 'mesenchymal stromal cell',\n",
              " 'SOD1G93A mouse model',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'Influence',\n",
              " 'Environment',\n",
              " 'Lifestyle',\n",
              " 'Incidence',\n",
              " 'Progress',\n",
              " 'Amyotrophic Lateral Sclerosis',\n",
              " 'German ALS',\n",
              " 'Population',\n",
              " 'ROCKALS',\n",
              " 'Protocol',\n",
              " 'Randomized PlaceboControlled DoubleBlind Phase IIa Trial',\n",
              " 'Safety',\n",
              " 'Tolerability',\n",
              " 'Efficacy',\n",
              " 'Rho Kinase',\n",
              " 'Inhibitor',\n",
              " 'Fasudil',\n",
              " 'Amyotrophic Lateral Sclerosis Hybrid Sterility',\n",
              " 'Meiotic Metaphase Arrest',\n",
              " 'Intersubspecific',\n",
              " 'Mouse',\n",
              " 'ROCKALS',\n",
              " 'Protocol',\n",
              " 'Randomized PlaceboControlled DoubleBlind Phase IIa Trial',\n",
              " 'Safety',\n",
              " 'Tolerability',\n",
              " 'Efficacy',\n",
              " 'Rho Kinase',\n",
              " 'Inhibitor',\n",
              " 'Fasudil',\n",
              " 'Amyotrophic Lateral Sclerosis',\n",
              " 'in vivo',\n",
              " 'determination',\n",
              " 'peripheral nervous system',\n",
              " 'immune activity',\n",
              " 'ALS',\n",
              " 'phase III trial',\n",
              " 'potential',\n",
              " 'treatment',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'Nursing Care',\n",
              " 'Clinical Trials',\n",
              " 'Qualitative Study',\n",
              " 'Views',\n",
              " 'Nordic Oncology',\n",
              " 'Hematology Nurses',\n",
              " 'Ethical Work Challenges Dysregulation',\n",
              " 'pathway',\n",
              " 'sporadic',\n",
              " 'familial',\n",
              " 'ALS',\n",
              " 'hypersalivation',\n",
              " 'patient',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'Significance',\n",
              " 'CSF',\n",
              " 'NfL',\n",
              " 'tau',\n",
              " 'ALS',\n",
              " 'Dyspnea',\n",
              " 'Amyotrophic Lateral Sclerosis RaschBased Development',\n",
              " 'Validation',\n",
              " 'PatientReported Outcome DALS15',\n",
              " 'Projected change',\n",
              " 'persistent',\n",
              " 'summer',\n",
              " 'weather',\n",
              " 'event',\n",
              " 'quasiresonant',\n",
              " 'amplification',\n",
              " 'FGF2',\n",
              " 'SOD1',\n",
              " 'ALS',\n",
              " 'mouse',\n",
              " 'in vivo',\n",
              " 'in vitro',\n",
              " 'KEFALAKES',\n",
              " 'Quantitative Susceptibility',\n",
              " 'MRI',\n",
              " 'Detect',\n",
              " 'Brain Iron',\n",
              " 'Amyotrophic Lateral Sclerosis Alberta wildfire',\n",
              " 'Apt contribution',\n",
              " 'anomalous',\n",
              " 'Association',\n",
              " 'attentiondeficithyperactivity disorder',\n",
              " 'ADHD',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'ALS',\n",
              " 'Provision',\n",
              " 'assistive technology device',\n",
              " 'people',\n",
              " 'ALS',\n",
              " 'Germany',\n",
              " 'platformcase management',\n",
              " 'Comprehensive',\n",
              " 'analysis',\n",
              " 'mutation',\n",
              " 'German',\n",
              " 'ALS',\n",
              " 'family Safety',\n",
              " 'efficacy',\n",
              " 'rasagiline',\n",
              " 'addon therapy',\n",
              " 'riluzole',\n",
              " 'patient',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'randomised',\n",
              " 'phase 2 trial',\n",
              " 'MUNIX',\n",
              " 'clinical trial',\n",
              " 'Real world',\n",
              " 'experience',\n",
              " 'Longitudinal sonographic',\n",
              " 'peripheral nerve',\n",
              " 'ALS',\n",
              " 'sonographic',\n",
              " 'peripheral nerve',\n",
              " 'ALS',\n",
              " 'ALS',\n",
              " 'disease',\n",
              " 'Global Hippocampal',\n",
              " 'Reductions',\n",
              " 'Local CA1',\n",
              " 'Shape',\n",
              " 'Deformations',\n",
              " 'Amyotrophic Lateral Sclerosis',\n",
              " 'Therapeutic decision',\n",
              " 'ALS',\n",
              " 'patient',\n",
              " 'clinical implication',\n",
              " 'Agedependent',\n",
              " 'neurodegeneration',\n",
              " 'organelle transport deficiency',\n",
              " 'mutant',\n",
              " 'TDP43',\n",
              " 'neuron',\n",
              " 'TDP43',\n",
              " 'aggregation',\n",
              " 'Differential',\n",
              " 'involvement',\n",
              " 'forearm muscle',\n",
              " 'ALS',\n",
              " 'sonographic',\n",
              " 'structural nerve',\n",
              " 'metabolic',\n",
              " 'endocrine',\n",
              " 'spinal',\n",
              " 'bulbar',\n",
              " 'muscular atrophy',\n",
              " 'Prognosis',\n",
              " 'patient',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'validation',\n",
              " 'personalised prediction model',\n",
              " 'Supplementary Data',\n",
              " 'Percutaneous endoscopic gastrostomy',\n",
              " 'jejunal extension',\n",
              " 'patient',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'Hotspot KIF5A',\n",
              " 'mutation',\n",
              " 'familial',\n",
              " 'ALS',\n",
              " 'Peripheral nerve atrophy',\n",
              " 'cerebrospinal fluid',\n",
              " 'progranulin',\n",
              " 'axonal damage',\n",
              " ...]"
            ]
          },
          "metadata": {},
          "execution_count": 22
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "nlp = spacy.load(\"en_ner_bc5cdr_md\")\n",
        "medicine_dict = ', '.join(medicine_dict)"
      ],
      "metadata": {
        "id": "1QPkETDyahqz",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "d7e94694-5235-441f-a634-088a2b6ac47d"
      },
      "execution_count": 27,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting https://s3-us-west-2.amazonaws.com/ai2-s2-scispacy/releases/v0.5.4/en_ner_bc5cdr_md-0.5.4.tar.gz\n",
            "  Using cached https://s3-us-west-2.amazonaws.com/ai2-s2-scispacy/releases/v0.5.4/en_ner_bc5cdr_md-0.5.4.tar.gz (119.8 MB)\n",
            "  Preparing metadata (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
            "Requirement already satisfied: spacy<3.8.0,>=3.7.4 in /usr/local/lib/python3.10/dist-packages (from en-ner-bc5cdr-md==0.5.4) (3.7.4)\n",
            "Requirement already satisfied: spacy-legacy<3.1.0,>=3.0.11 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (3.0.12)\n",
            "Requirement already satisfied: spacy-loggers<2.0.0,>=1.0.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (1.0.5)\n",
            "Requirement already satisfied: murmurhash<1.1.0,>=0.28.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (1.0.10)\n",
            "Requirement already satisfied: cymem<2.1.0,>=2.0.2 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (2.0.8)\n",
            "Requirement already satisfied: preshed<3.1.0,>=3.0.2 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (3.0.9)\n",
            "Requirement already satisfied: thinc<8.3.0,>=8.2.2 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (8.2.3)\n",
            "Requirement already satisfied: wasabi<1.2.0,>=0.9.1 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (1.1.2)\n",
            "Requirement already satisfied: srsly<3.0.0,>=2.4.3 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (2.4.8)\n",
            "Requirement already satisfied: catalogue<2.1.0,>=2.0.6 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (2.0.10)\n",
            "Requirement already satisfied: weasel<0.4.0,>=0.1.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (0.3.4)\n",
            "Requirement already satisfied: typer<0.10.0,>=0.3.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (0.9.0)\n",
            "Requirement already satisfied: smart-open<7.0.0,>=5.2.1 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (6.4.0)\n",
            "Requirement already satisfied: tqdm<5.0.0,>=4.38.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (4.66.2)\n",
            "Requirement already satisfied: requests<3.0.0,>=2.13.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (2.31.0)\n",
            "Requirement already satisfied: pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (2.6.4)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (3.1.3)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (67.7.2)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (24.0)\n",
            "Requirement already satisfied: langcodes<4.0.0,>=3.2.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (3.3.0)\n",
            "Requirement already satisfied: numpy>=1.19.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (1.25.2)\n",
            "Requirement already satisfied: annotated-types>=0.4.0 in /usr/local/lib/python3.10/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (0.6.0)\n",
            "Requirement already satisfied: pydantic-core==2.16.3 in /usr/local/lib/python3.10/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (2.16.3)\n",
            "Requirement already satisfied: typing-extensions>=4.6.1 in /usr/local/lib/python3.10/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (4.10.0)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (3.3.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (3.6)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (2024.2.2)\n",
            "Requirement already satisfied: blis<0.8.0,>=0.7.8 in /usr/local/lib/python3.10/dist-packages (from thinc<8.3.0,>=8.2.2->spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (0.7.11)\n",
            "Requirement already satisfied: confection<1.0.0,>=0.0.1 in /usr/local/lib/python3.10/dist-packages (from thinc<8.3.0,>=8.2.2->spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (0.1.4)\n",
            "Requirement already satisfied: click<9.0.0,>=7.1.1 in /usr/local/lib/python3.10/dist-packages (from typer<0.10.0,>=0.3.0->spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (8.1.7)\n",
            "Requirement already satisfied: cloudpathlib<0.17.0,>=0.7.0 in /usr/local/lib/python3.10/dist-packages (from weasel<0.4.0,>=0.1.0->spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (0.16.0)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.10/dist-packages (from jinja2->spacy<3.8.0,>=3.7.4->en-ner-bc5cdr-md==0.5.4) (2.1.5)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "doc = nlp(medicine_dict)"
      ],
      "metadata": {
        "id": "nW0fBLbJapzb"
      },
      "execution_count": 28,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "all_disease = []\n",
        "for ent in doc.ents:\n",
        "  if ent.label_ == 'DISEASE':\n",
        "    all_disease.append(ent.text)"
      ],
      "metadata": {
        "id": "qOIbEVl2awyR"
      },
      "execution_count": 34,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "all_disease"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "rN-xP_EcNJXo",
        "outputId": "8575233a-e3b2-49ff-b9d6-db5fbf0dae7e"
      },
      "execution_count": 35,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['COURAGEALS',\n",
              " 'ALS',\n",
              " 'Hereditary Polyneuropathies',\n",
              " 'ALS',\n",
              " 'Epilepsy',\n",
              " 'encephalopathy',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'COURAGEALS',\n",
              " 'muscular atrophy',\n",
              " 'muscular atrophy',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'ALS',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'immunemediated neuropathy',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'Muscular Atrophy',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'CX3CL1CX3CR1 Axis',\n",
              " 'ALS',\n",
              " 'nonambulant',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'hemiplegia',\n",
              " 'muscular atrophy',\n",
              " 'Muscular Atrophy',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'lateral sclerosis',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'Muscular Atrophy',\n",
              " 'muscular atrophy',\n",
              " 'Hemiplegic',\n",
              " 'Visual Field Disorder Amyotrophe',\n",
              " 'Hypercoagulability',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'neurogenic thoracic outlet syndrome',\n",
              " 'pain',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'ALS',\n",
              " 'ALS',\n",
              " 'fatigue',\n",
              " 'muscular atrophy',\n",
              " 'ALS',\n",
              " 'TRICALS',\n",
              " 'ALS',\n",
              " 'Pain',\n",
              " 'Lateral Sclerosis Major',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'Materialpdf',\n",
              " 'Muscular Atrophy',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'Muscular Atrophy',\n",
              " 'ALS',\n",
              " 'ALS',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'Pain',\n",
              " 'ALS',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'pain',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'muscular atrophy',\n",
              " 'Motor neuron disease',\n",
              " 'dementia',\n",
              " 'Neurodevelopmental Disorders',\n",
              " 'Lateral Sclerosis ALS',\n",
              " 'death',\n",
              " 'SALS',\n",
              " 'FALS',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'muscular atrophy',\n",
              " 'fatigue',\n",
              " 'muscular atrophy',\n",
              " 'muscular atrophy',\n",
              " 'Muscular Atrophy',\n",
              " 'ALS',\n",
              " 'muscular atrophy',\n",
              " 'Muscular Atrophy',\n",
              " 'deficiency syndrome',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'ALS',\n",
              " 'SALS',\n",
              " 'FALS',\n",
              " 'memory impairment',\n",
              " 'axonal neuropathy',\n",
              " 'middleaged',\n",
              " 'Muscular Atrophy',\n",
              " 'Peripheral neuropathy',\n",
              " 'ALS',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'ALS',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'Seizures',\n",
              " 'Epilepsy',\n",
              " 'ALS',\n",
              " 'ALS',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'hereditary spastic paraplegia',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'muscular atrophy',\n",
              " 'Dyspnea',\n",
              " 'ALS',\n",
              " 'Respiratory Impairment',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'epilepsy',\n",
              " 'Epileptic Encephalopathy',\n",
              " 'neuromuscular disorder',\n",
              " 'ALS',\n",
              " 'epileptic encephalopathy',\n",
              " 'ALS',\n",
              " 'cancer',\n",
              " 'materialpdf',\n",
              " 'Lateral Sclerosis CDNF rescue motor neuron',\n",
              " 'ALS',\n",
              " 'neurodevelopmental disease',\n",
              " 'muscular atrophy',\n",
              " 'ALS',\n",
              " 'neurodegenerative disorder',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'Dyspnea',\n",
              " 'ALS',\n",
              " 'Respiratory Impairment',\n",
              " 'ALS',\n",
              " 'ALS',\n",
              " 'Shock',\n",
              " 'ALS',\n",
              " 'ALS',\n",
              " 'muscular atrophy',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'ALS',\n",
              " 'dyspnea',\n",
              " 'Cerebral Cavernous Malformations',\n",
              " 'hypersalivation',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'ALS',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'Dyspnea',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'respiratory impairment',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'ALS',\n",
              " 'dyspnea',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'ALS',\n",
              " 'ALS',\n",
              " 'der',\n",
              " 'Eine hochkalorische fettreiche',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'ALS',\n",
              " 'Lateral Sclerosis',\n",
              " 'ALS',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'ALS',\n",
              " 'hypersalivation',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'ALS',\n",
              " 'Dyspnea',\n",
              " 'ALS',\n",
              " 'Lateral Sclerosis Alberta',\n",
              " 'attentiondeficithyperactivity disorder',\n",
              " 'ADHD',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'ALS',\n",
              " 'ALS',\n",
              " 'ALS',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'ALS',\n",
              " 'ALS',\n",
              " 'ALS',\n",
              " 'ALS',\n",
              " 'neurodegeneration',\n",
              " 'transport deficiency',\n",
              " 'ALS',\n",
              " 'muscular atrophy',\n",
              " 'Prognosis',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'ALS',\n",
              " 'Peripheral nerve atrophy',\n",
              " 'axonal damage',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'neurodegeneration',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'Lateral Sclerosis']"
            ]
          },
          "metadata": {},
          "execution_count": 35
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def process_list(word_list):\n",
        "    word_list = [word.strip() for word in word_list]\n",
        "    lower_words = [word.lower() for word in word_list]\n",
        "    unique_words = list(set(lower_words))\n",
        "    sorted_words = sorted(unique_words)\n",
        "\n",
        "    return sorted_words"
      ],
      "metadata": {
        "id": "89aMTNL3NmlM"
      },
      "execution_count": 36,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "**Завдання 1 та 2 , всі хвороби з тексту + видалення дублікатів , переведення в нижній регістр та сортування**"
      ],
      "metadata": {
        "id": "csx8frKrN-J7"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "all_disease = process_list(all_disease)\n",
        "all_disease"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Jaj4sEvQNzR_",
        "outputId": "7eb032ac-4b2d-42d4-fad4-68b27f5af9c3"
      },
      "execution_count": 37,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['adhd',\n",
              " 'als',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'attentiondeficithyperactivity disorder',\n",
              " 'axonal damage',\n",
              " 'axonal neuropathy',\n",
              " 'cancer',\n",
              " 'cerebral cavernous malformations',\n",
              " 'courageals',\n",
              " 'cx3cl1cx3cr1 axis',\n",
              " 'death',\n",
              " 'deficiency syndrome',\n",
              " 'dementia',\n",
              " 'der',\n",
              " 'dyspnea',\n",
              " 'eine hochkalorische fettreiche',\n",
              " 'encephalopathy',\n",
              " 'epilepsy',\n",
              " 'epileptic encephalopathy',\n",
              " 'fals',\n",
              " 'fatigue',\n",
              " 'hemiplegia',\n",
              " 'hemiplegic',\n",
              " 'hereditary polyneuropathies',\n",
              " 'hereditary spastic paraplegia',\n",
              " 'hypercoagulability',\n",
              " 'hypersalivation',\n",
              " 'immunemediated neuropathy',\n",
              " 'lateral sclerosis',\n",
              " 'lateral sclerosis alberta',\n",
              " 'lateral sclerosis als',\n",
              " 'lateral sclerosis cdnf rescue motor neuron',\n",
              " 'lateral sclerosis major',\n",
              " 'materialpdf',\n",
              " 'memory impairment',\n",
              " 'middleaged',\n",
              " 'motor neuron disease',\n",
              " 'muscular atrophy',\n",
              " 'neurodegeneration',\n",
              " 'neurodegenerative disorder',\n",
              " 'neurodevelopmental disease',\n",
              " 'neurodevelopmental disorders',\n",
              " 'neurogenic thoracic outlet syndrome',\n",
              " 'neuromuscular disorder',\n",
              " 'nonambulant',\n",
              " 'pain',\n",
              " 'peripheral nerve atrophy',\n",
              " 'peripheral neuropathy',\n",
              " 'prognosis',\n",
              " 'respiratory impairment',\n",
              " 'sals',\n",
              " 'seizures',\n",
              " 'shock',\n",
              " 'transport deficiency',\n",
              " 'tricals',\n",
              " 'visual field disorder amyotrophe']"
            ]
          },
          "metadata": {},
          "execution_count": 37
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "all_medical_terms = []\n",
        "for ent in doc.ents:\n",
        "  all_medical_terms.append(ent.text)"
      ],
      "metadata": {
        "id": "siDQz0GAN5mE"
      },
      "execution_count": 38,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "**Завдання 3 - вивід всіх медичних термінів**"
      ],
      "metadata": {
        "id": "Iceg0BxxQZ5P"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "all_medical_terms = process_list(all_medical_terms)\n",
        "all_medical_terms"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "CpDzTPT8QGxH",
        "outputId": "11aef680-6874-4fba-90a2-8f794fd30110"
      },
      "execution_count": 41,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['adhd',\n",
              " 'als',\n",
              " 'amyotrophic lateral sclerosis',\n",
              " 'apt',\n",
              " 'arfgef1',\n",
              " 'attentiondeficithyperactivity disorder',\n",
              " 'axonal damage',\n",
              " 'axonal neuropathy',\n",
              " 'calcium',\n",
              " 'cancer',\n",
              " 'cerebral cavernous malformations',\n",
              " 'comedication',\n",
              " 'courageals',\n",
              " 'creatine',\n",
              " 'creatinine',\n",
              " 'cx3cl1cx3cr1 axis',\n",
              " 'death',\n",
              " 'deficiency syndrome',\n",
              " 'dementia',\n",
              " 'der',\n",
              " 'dyspnea',\n",
              " 'dyspneaalsscale dals15',\n",
              " 'edaravone',\n",
              " 'eine hochkalorische fettreiche',\n",
              " 'encephalopathy',\n",
              " 'epilepsy',\n",
              " 'epileptic encephalopathy',\n",
              " 'fals',\n",
              " 'fasudil',\n",
              " 'fatigue',\n",
              " 'glutamate',\n",
              " 'hemiplegia',\n",
              " 'hemiplegic',\n",
              " 'hereditary polyneuropathies',\n",
              " 'hereditary spastic paraplegia',\n",
              " 'hypercoagulability',\n",
              " 'hypersalivation',\n",
              " 'immunemediated neuropathy',\n",
              " 'iron',\n",
              " 'lateral sclerosis',\n",
              " 'lateral sclerosis alberta',\n",
              " 'lateral sclerosis als',\n",
              " 'lateral sclerosis cdnf rescue motor neuron',\n",
              " 'lateral sclerosis major',\n",
              " 'levosimendan',\n",
              " 'materialpdf',\n",
              " 'memory impairment',\n",
              " 'middleaged',\n",
              " 'motor neuron disease',\n",
              " 'muscular atrophy',\n",
              " 'neurodegeneration',\n",
              " 'neurodegenerative disorder',\n",
              " 'neurodevelopmental disease',\n",
              " 'neurodevelopmental disorders',\n",
              " 'neurogenic thoracic outlet syndrome',\n",
              " 'neuromuscular disorder',\n",
              " 'nonambulant',\n",
              " 'nusinersen',\n",
              " 'oligonucleotide',\n",
              " 'pain',\n",
              " 'peripheral nerve atrophy',\n",
              " 'peripheral neuropathy',\n",
              " 'potassium',\n",
              " 'prognosis',\n",
              " 'progranulin',\n",
              " 'rasagiline',\n",
              " 'respiratory impairment',\n",
              " 'riluzole',\n",
              " 'sals',\n",
              " 'seizures',\n",
              " 'shock',\n",
              " 'tauroursodeoxycholic acid',\n",
              " 'transcriptomewide',\n",
              " 'transport deficiency',\n",
              " 'tricals',\n",
              " 'visual field disorder amyotrophe']"
            ]
          },
          "metadata": {},
          "execution_count": 41
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "X3S9lRbMQTzh"
      },
      "execution_count": null,
      "outputs": []
    }
  ]
}
